Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ABT-494

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BackgroundAnti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
AIMS Upadacitinib (ABT-494) is a selective Janus kinase 1 inhibitor being developed for treatment of auto-immune inflammatory… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2017
2017
Background ABT-494 is a selective Janus Kinase 1 inhibitor. In two Phase 2b studies in subjects with rheumatoid arthritis, 6 mg… Expand
Is this relevant?
Highly Cited
2016
Highly Cited
2016
To evaluate the efficacy and safety of ABT‐494, a selective JAK‐1 inhibitor, in patients with moderate‐to‐severe rheumatoid… Expand
Is this relevant?
Highly Cited
2016
Highly Cited
2016
To compare the efficacy and safety of ABT‐494, a novel selective JAK‐1 inhibitor, with placebo in patients with moderate‐to… Expand
Is this relevant?
2016
2016
BackgroundABT-494 is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Review
2016
Review
2016
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by synovial inflammation and joint destruction… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
Background Janus activated kinase (Jak) inhibition has shown clinical benefits in treatment of rheumatoid arthritis (RA). However… Expand
Is this relevant?
2014
2014
Background Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can… Expand
Is this relevant?